Related Experiment Video
Updated: Apr 23, 2026
Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens
Published on: July 29, 2011
Characterization of a novel anti-cancer compound for astrocytomas
Sang Y Lee1, Becky Slagle-Webb1, Elias Rizk1
1Department of Neurosurgery, Pennsylvania State University College of Medicine, Penn State M.S. Hershey Medical Center, Hershey, Pennsylvania, United States of America.
Abstract:
The standard chemotherapy for brain tumors is temozolomide (TMZ), however, as many as 50% of brain tumors are reportedly TMZ resistant leaving patients without a chemotherapeutic option. We performed serial screening of TMZ resistant astrocytoma cell lines, and identified compounds that are cytotoxic to these cells. The most cytotoxic compound was an analog of thiobarbituric acid that we refer to as CC-I. There is a dose-dependent cytotoxic effect of CC-I in TMZ resistant astrocytoma cells. Cell death appears to occur via apoptosis. Following CC-I exposure, there was an increase in astrocytoma cells in the S and G2/M phases. In in vivo athymic (nu/nu) nude mice subcutaneous and intracranial tumor models, CC-I completely inhibited tumor growth without liver or kidney toxicity. Molecular modeling and enzyme activity assays indicate that CC-I selectively inhibits topoisomerase IIα similar to other drugs in its class, but its cytotoxic effects on astrocytoma cells are stronger than these compounds. The cytotoxic effect of CC-I is stronger in cells expressing unmethylated O6-methylguanine methyltransferase (MGMT) but is still toxic to cells with methylated MGMT. CC-I can also enhance the toxic effect of TMZ on astrocytoma when the two compounds are combined. In conclusion, we have identified a compound that is effective against astrocytomas including TMZ resistant astrocytomas in both cell culture and in vivo brain tumor models. The enhanced cytotoxicity of CC-I and the safety profile of this family of drugs could provide an interesting tool for broader evaluation against brain tumors.
Insights
A novel thiobarbituric acid analog, CC-I, shows potent cytotoxicity against temozolomide-resistant brain tumors. This compound effectively inhibits tumor growth in vivo with no observed toxicity, offering a promising new therapeutic avenue.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Standard brain tumor chemotherapy, temozolomide (TMZ), faces resistance in up to 50% of cases.
- Development of novel therapeutic agents is crucial for overcoming TMZ resistance in astrocytoma.
Purpose of the Study:
- To identify and characterize novel compounds with cytotoxic activity against TMZ-resistant astrocytoma cells.
- To evaluate the efficacy and safety of the identified compound, CC-I, in preclinical brain tumor models.
Main Methods:
- Serial screening of TMZ-resistant astrocytoma cell lines to identify cytotoxic compounds.
- In vitro assessment of CC-I's dose-dependent cytotoxicity, cell death mechanism (apoptosis), and cell cycle effects.
- In vivo evaluation of CC-I in subcutaneous and intracranial tumor models in nude mice.
- Molecular modeling and enzyme activity assays to determine CC-I's mechanism of action, including topoisomerase IIα inhibition.
- Assessment of CC-I's efficacy in combination with TMZ and its activity in cells with varying O6-methylguanine methyltransferase (MGMT) methylation status.
Main Results:
- CC-I, a thiobarbituric acid analog, demonstrated significant dose-dependent cytotoxicity against TMZ-resistant astrocytoma cells, inducing apoptosis and altering cell cycle phases (S and G2/M).
- In vivo studies showed complete inhibition of tumor growth in both subcutaneous and intracranial models without observable liver or kidney toxicity.
- CC-I selectively inhibits topoisomerase IIα, exhibiting stronger cytotoxic effects than other compounds in its class, and is effective against both methylated and unmethylated MGMT expressing cells.
- CC-I enhanced the cytotoxic effect of TMZ when used in combination therapy.
Conclusions:
- CC-I is a potent anti-cancer compound effective against both TMZ-sensitive and TMZ-resistant astrocytomas in vitro and in vivo.
- The compound exhibits a favorable safety profile and a promising mechanism of action, warranting further investigation for brain tumor treatment.
- CC-I represents a potential new therapeutic strategy for brain tumors, particularly those resistant to standard chemotherapy.
More Related Videos
09:02Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
10:13Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice
Published on: August 12, 2014